Statement on Improving Medical Access

The Denka Group recognizes the issue of access to medical care as an important human rights issue. Many people, especially in developing countries, find it difficult to receive appropriate medical care due to vulnerable medical infrastructures and environments where access to medical care is restricted. The spread of infectious diseases is particularly serious, and a vicious cycle is created in which many people lose their lives due to further infections caused by the fact that tests are not conducted even for diseases that can be cured with early diagnosis. Improving medical access will reduce such people and protect the lives and livelihoods of people around the world. The Denka Group will continue contributing to improving medical access for all people through our diagnostic reagents and healthcare services businesses, thereby helping achieve the materiality of "extending healthy life expectancy and correcting health disparities" set out in our management plan.

Efforts in Developing Countries for Pharmaceutical Development

The Denka Group has provided an Ebola virus antigen rapid test kit, co-developed with Professor Yoshito Takada of Hokkaido University, to the Democratic Republic of the Congo (DRC) through JICA. The kit has been used for initial testing during several outbreaks of Ebola hemorrhagic fever in the DRC, contributing to the prevention of its spread. The kit can provide results in about 10 minutes, can be stored at room temperature, and does not require any special equipment, making it usable in areas where infrastructure is lacking. Following its approval for manufacturing and marketing in Japan by the Pharmaceuticals and Medical Devices Agency (PMDA) in 2021, the kit received formal usage approval from the National Institute of Biomedical Research of the DRC in 2024, and is expected to contribute to rapid diagnosis and infection control in the event of an outbreak of Ebola hemorrhagic fever.

Proper Promotion Activities of Pharmaceuticals

Denka complies with the "Code of Practice" established by the Japan Pharmaceutical Manufacturers Association and the "In Vitro Diagnostic Reagents Promotion Code" established by the Japan Clinical Reagent Manufacturers Association. Denka takes all responsibility for promotion, including the conduct of medical information representatives, and has established an internal system for conducting appropriate promotion and is engaged in responsible advertising and marketing of pharmaceuticals.

• ※The term "pharmaceuticals" as used hereinafter refers to both medical use pharmaceuticals and in vitro diagnostic pharmaceuticals.

<Promotion Code for Prescription Pharmaceutical Products and In-Vitro Diagnostics, Section 1: Denka’s Responsibilities>

1. Appoint appropriate persons as medical representatives and continue to provide education and training.
2. Provide information on indications (purpose of use), dosage and method of use (method of operation), or sensitivity, accuracy, reproducibility (performance), correlation, etc. in a proper manner based on data with a clear scientific basis.
3. Accurately and promptly collect and communicate pharmaceutical information.
4. Establish an internal system to ensure that activities are conducted in compliance with relevant laws and regulations and voluntary regulations.

As a company that plays a part in medical care, Denka conducts responsible information activities for pharmaceuticals and recognizes that printed promotional materials, advertisements in specialist publications (print), promotional audiovisual materials such as slides and videos for advertising, and other promotional materials are important means of providing pharmaceutical information. In the preparation and use of these materials, Denka complies with the Pharmaceutical and Medical Device Act (Act on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices) and the Guidelines for Information Provision Activities on Prescription Drugs, the Guidelines for Information Provision Activities on In-Vitro Diagnostic Drugs, the Guidelines for Preparing Product Information Summaries for Prescription Drugs, and the Denka "Promotion Code" established in accordance with these laws and guidelines, ensuring that the content is based on scientific evidence and is accurate, fair, and objective.